171 related articles for article (PubMed ID: 15461065)
1. Meta-analysis of randomised controlled prostaglandin E1 studies in peripheral arterial occlusive disease stages III and IV.
Creutzig A; Lehmacher W; Elze M
Vasa; 2004 Aug; 33(3):137-44. PubMed ID: 15461065
[TBL] [Abstract][Full Text] [Related]
2. A meta-analysis of randomized placebo control trials in Fontaine stages III and IV peripheral occlusive arterial disease.
Loosemore TM; Chalmers TC; Dormandy JA
Int Angiol; 1994 Jun; 13(2):133-42. PubMed ID: 7525794
[TBL] [Abstract][Full Text] [Related]
3. [Prostaglandin E1 in stage III and IV arterial occlusive diseases. results of a multicenter study].
Trübestein G; Ludwig M; Diehm C; Gruss JD; Horsch S
Dtsch Med Wochenschr; 1987 Jun; 112(24):955-9. PubMed ID: 3297596
[TBL] [Abstract][Full Text] [Related]
4. Treatment of patients with peripheral arterial occlusive disease Fontaine stage IV with intravenous iloprost and PGE1: a randomized open controlled study.
Altstaedt HO; Berzewski B; Breddin HK; Brockhaus W; Bruhn HD; Cachovan M; Diehm C; Dörrler J; Franke CS; Gruss JD
Prostaglandins Leukot Essent Fatty Acids; 1993 Aug; 49(2):573-8. PubMed ID: 7692455
[TBL] [Abstract][Full Text] [Related]
5. Are there predictors for the outcome of a PGE1 treatment in peripheral arterial disease with critical limb ischaemia?
Heidrich H; Schmidt T; Fahrig C
Vasa; 2005 May; 34(2):101-7. PubMed ID: 15968891
[TBL] [Abstract][Full Text] [Related]
6. Two randomised and placebo-controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. The Oral Iloprost in severe Leg Ischaemia Study Group.
Eur J Vasc Endovasc Surg; 2000 Oct; 20(4):358-62. PubMed ID: 11038148
[TBL] [Abstract][Full Text] [Related]
7. Intensive vascular training in stage IIb of peripheral arterial occlusive disease. The additive effects of intravenous prostaglandin E1 or intravenous pentoxifylline during training.
Scheffler P; de la Hamette D; Gross J; Mueller H; Schieffer H
Circulation; 1994 Aug; 90(2):818-22. PubMed ID: 8044953
[TBL] [Abstract][Full Text] [Related]
8. [Combination of profundaplasty and pharmacotherapy in stage III/IV peripheral arterial occlusive disease].
Gruss JD
Langenbecks Arch Chir Suppl Kongressbd; 1998; 115():1252-5. PubMed ID: 9931851
[TBL] [Abstract][Full Text] [Related]
9. Effects of adjuvant PGE1 therapy following profundaplasty in patients with severe limb ischaemia. Early and long-term results.
Gruss JD
Vasa; 1997 May; 26(2):117-21. PubMed ID: 9174388
[TBL] [Abstract][Full Text] [Related]
10. Prostanoids for critical limb ischaemia.
Ruffolo AJ; Romano M; Ciapponi A
Cochrane Database Syst Rev; 2010 Jan; (1):CD006544. PubMed ID: 20091595
[TBL] [Abstract][Full Text] [Related]
11. Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease.
Böger RH; Bode-Böger SM; Thiele W; Creutzig A; Alexander K; Frölich JC
J Am Coll Cardiol; 1998 Nov; 32(5):1336-44. PubMed ID: 9809945
[TBL] [Abstract][Full Text] [Related]
12. Intravenous prostaglandin E1 versus pentoxifylline therapy in chronic arterial occlusive disease--a controlled randomised multicenter study.
Trübestein G; von Bary S; Breddin K; Diehm C; Gruss JD; Heinrich H; Horsch S; Kriessmann A; Maass U; Martin M
Vasa Suppl; 1989; 28():44-9. PubMed ID: 2692200
[TBL] [Abstract][Full Text] [Related]
13. Effects of intravenous prostaglandin E1 on arterial compliance: a randomized controlled trial.
Mlekusch W; Schillinger M; Sabeti S; Al-Awami M; Gschwandtner M; Minar E
Vasa; 2004 Aug; 33(3):131-6. PubMed ID: 15461064
[TBL] [Abstract][Full Text] [Related]
14. [Mechanisms of action of prostaglandin E1 in therapy of peripheral arterial occlusive diseases].
Weiss T
Vasa; 2003 Nov; 32(4):187-92. PubMed ID: 14694766
[TBL] [Abstract][Full Text] [Related]
15. [Treating chronic occlusive arterial disease].
Rottman M; Koepchen J; Angelkort B
MMW Fortschr Med; 2005 May; 147(18):30-3. PubMed ID: 15934585
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of prostaglandin E1 in the treatment of lower extremity ischemic ulcers secondary to peripheral vascular occlusive disease. Results of a prospective randomized, double-blind, multicenter clinical trial.
Schuler JJ; Flanigan DP; Holcroft JW; Ursprung JJ; Mohrland JS; Pyke J
J Vasc Surg; 1984 Jan; 1(1):160-70. PubMed ID: 6384558
[TBL] [Abstract][Full Text] [Related]
17. Low-dose iloprost infusions compared to the standard dose in patients with peripheral arterial occlusive disease Fontaine stage IV. DAWID Study Group.
Beischer W; Dembski JC; Gruss JD; Hofgärtner F; Horsch A; Horsch S; Kuhlmann HW; Loose DA; Mietaschk A; Schwilden ED; Spengel F; Spitzer W; Staben P; Stallkamp B; Stürzebecher CS; Tokhi M; von Bilderling P
Vasa; 1998 Feb; 27(1):15-9. PubMed ID: 9540427
[TBL] [Abstract][Full Text] [Related]
18. Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter six-month outcomes in patients with critical leg ischemia.
Brass EP; Anthony R; Dormandy J; Hiatt WR; Jiao J; Nakanishi A; McNamara T; Nehler M;
J Vasc Surg; 2006 Apr; 43(4):752-9. PubMed ID: 16616232
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of anti-ischemic action of prostaglandin E1 in peripheral arterial occlusive disease.
Schrör K; Hohlfeld T
Vasa; 2004 Aug; 33(3):119-24. PubMed ID: 15461062
[TBL] [Abstract][Full Text] [Related]
20. Transcutaneous oxygen pressure as predictive parameter for ulcer healing in endstage vascular patients treated with spinal cord stimulation.
Claeys LG; Horsch S
Int Angiol; 1996 Dec; 15(4):344-9. PubMed ID: 9127776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
